Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.
Lancet (London, England)
|
December 17, 2016
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The Journal of Clinical Investigation
|
August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy
Leisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature
|
February 15, 2018
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, et al.
Psychological Bulletin
|
February 2, 2026
A meta-analytic review of cultural variation in affect valuation
Jeanne L Tsai, Daniel S Chen, Angela M Yang, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.
Lancet (London, England)
|
December 17, 2016
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The Journal of Clinical Investigation
|
August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy
Leisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature
|
February 15, 2018
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, et al.
Psychological Bulletin
|
February 2, 2026
A meta-analytic review of cultural variation in affect valuation
Jeanne L Tsai, Daniel S Chen, Angela M Yang, et al.
Page
of 4